A detailed history of State Street Corp transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 117,084 shares of BDTX stock, worth $545,611. This represents 0.0% of its overall portfolio holdings.

Number of Shares
117,084
Previous 115,784 1.12%
Holding current value
$545,611
Previous $325,000 82.46%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.67 - $5.74 $3,471 - $7,462
1,300 Added 1.12%
117,084 $593,000
Q4 2023

Feb 14, 2024

BUY
$1.77 - $3.03 $69,738 - $119,381
39,400 Added 51.58%
115,784 $325,000
Q2 2022

Aug 15, 2022

SELL
$1.5 - $3.63 $439,317 - $1.06 Million
-292,878 Reduced 79.31%
76,384 $188,000
Q1 2022

May 16, 2022

BUY
$2.66 - $5.61 $12,259 - $25,856
4,609 Added 1.26%
369,262 $1.02 Million
Q4 2021

Feb 14, 2022

BUY
$5.18 - $8.48 $46,361 - $75,896
8,950 Added 2.52%
364,653 $1.94 Million
Q3 2021

Nov 15, 2021

BUY
$8.46 - $12.42 $180,637 - $265,191
21,352 Added 6.39%
355,703 $3.01 Million
Q2 2021

Aug 16, 2021

SELL
$12.19 - $28.17 $17.8 Million - $41.1 Million
-1,460,287 Reduced 81.37%
334,351 $4.08 Million
Q1 2021

May 17, 2021

BUY
$22.23 - $34.75 $21.6 Million - $33.8 Million
972,021 Added 118.16%
1,794,638 $43.5 Million
Q4 2020

Feb 16, 2021

BUY
$29.47 - $35.0 $16 Million - $19 Million
543,698 Added 194.93%
822,617 $26.4 Million
Q3 2020

Nov 10, 2020

BUY
$26.17 - $43.07 $1.28 Million - $2.1 Million
48,801 Added 21.21%
278,919 $8.43 Million
Q2 2020

Aug 14, 2020

BUY
$22.3 - $44.8 $916,418 - $1.84 Million
41,095 Added 21.74%
230,118 $9.7 Million
Q1 2020

May 11, 2020

BUY
$18.18 - $39.3 $3.44 Million - $7.43 Million
189,023 New
189,023 $4.72 Million

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $169M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.